Form 4: ResMed CFO Brett Sandercock Executes Pre-Arranged Stock Option Exercises and Share Sale

ResMed's Chief Financial Officer, Brett Sandercock, completed a series of pre-arranged transactions on July 1, 2025, involving the exercise of stock options and the subsequent sale of common stock under a Rule 10b5-1 plan.

Summary

• On July 1, 2025, Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), engaged in multiple stock transactions.
• Mr. Sandercock exercised options to acquire 1,966 shares of ResMed Common Stock at an exercise price of $101.64 per share.
• Concurrently, he exercised options to acquire an additional 917 shares of ResMed Common Stock, also at an exercise price of $101.64 per share.
• Following these acquisitions, Mr. Sandercock's direct beneficial ownership of common stock was 88,166 shares.
• On the same date, Mr. Sandercock sold 3,883 shares of ResMed Common Stock at a price of $256.99 per share.
• After all reported transactions, Mr. Sandercock's direct beneficial ownership of common stock stands at 84,283 shares.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which was adopted on February 19, 2025.
• The options exercised were part of a grant that first became exercisable on November 11, 2019, and are set to expire on November 14, 2025, with options vesting 1/3 per year.
• Following the option exercises, Mr. Sandercock's beneficial ownership of derivative securities (options) decreased from 8,917 to 8,000.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged Rule 10b5-1 plan mitigates concerns about opportunistic selling. The transactions represent a normal part of executive compensation and value realization.

Positives

• The exercise of stock options by the CFO indicates the realization of value from long-term incentive compensation.
• The sale price of $256.99 per share is significantly higher than the exercise price of $101.64, demonstrating a substantial gain for the CFO on the exercised options.

Negatives

• The sale of 3,883 shares by a key executive, even if pre-arranged, could be perceived by some investors as a slight negative, though the Rule 10b5-1 plan mitigates concerns about opportunistic selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025."
• "Represents date options first become exercisable. Options vest 1/3 per year."

Industry Context

This filing is a standard disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive dynamics within the medical device or sleep apnea market. It reflects an individual executive's compensation realization.

Stakeholder Impact

• Shareholders: May observe the CFO's stock sale, which is part of a pre-arranged plan, and note the significant profit realized from option exercises. This is a routine disclosure of executive compensation activity.

Key Dates

Keywords

ResMed, RMD, SEC Form 4, Insider Trading, Stock Options, CFO, Stock Sale, Rule 10b5-1 Plan, Executive Compensation